Yesterday (January 14th), Shanghai Huiwen Biology Technology Co., Ltd. (hereinafter referred to as Huiwen Biology) issued a notice titled “Announcement on the Death of One of the Company’s Actual Controllers and the Intended Change of Actual Controllers” (hereinafter referred to as the “Announcement”), stating that one of the company’s actual controllers, Liu Guiyun, passed away recently due to illness. According to a previous announcement by Huiwen Biology, Liu Guiyun was born in March 1939 and was 85 years old at the time of passing.
As per the Announcement, Liu Guiyun, as one of the pioneers in the transformation of Chinese scientific achievements, has achieved many groundbreaking accomplishments in areas such as plant cell tissue culture, natural product isolation and purification, functional research, and human reproductive endocrinology. Her efforts have led to the development of over 200 functional compounds derived from plants, laying a solid foundation for the development of Huiwen Biology.
At the same time, Liu Guiyun was also one of the first bio-tech research and development personnel to establish private science and technology enterprises in China in the 1980s. She subsequently served as the Vice President of the First Women Entrepreneurs Association of the National Federation of Industry and Commerce, the first President and Honorary President of the Women Entrepreneurs Association of the Guangdong Federation of Industry and Commerce.
The Board of Directors of Huiwen Biology stated that Liu Guiyun’s rigor, harmony, and innovative spirit have become a profound source of the company’s culture, leaving an indelible mark in the hearts of the employees. Throughout her life, she has always cared for others sincerely, influencing everyone around her with her kindness and selflessness.
In the Announcement, the Directors, Supervisors, senior management, and all employees of Huiwen Biology expressed their highest respect and heartfelt gratitude for Liu Guiyun’s hard work and outstanding contributions to the company. They deeply mourned her passing and extended their heartfelt condolences to Liu Guiyun’s family.
The Board of Directors of Huiwen Biology also mentioned that Liu Guiyun held approximately 1.9809 million shares of Huiwen Biology, accounting for 7.40% of the total share capital of the company. The procedures for inheriting the shares held by Liu Guiyun will be handled in accordance with relevant laws and regulations, and Huiwen Biology will fulfill its disclosure obligations promptly based on the progress of the subsequent matters. Currently, the Board of Directors, Supervisory Board, and senior management team of the company are functioning normally, and the company’s operations are proceeding as usual.
According to the “HUIWEN BIOLOGY” public account, Liu Guiyun was the founder of Huiwen Biology and originally established Shenzhen Wenda Industrial Co., Ltd. in 1985, which was the predecessor of Huiwen Biology. In 2000, Shenzhen Wenda Industrial Co., Ltd. shifted its focus to Shanghai, and Liu Guiyun, along with a group of scientists from the Chinese Academy of Sciences, founded Huiwen Biology in 2001, which was based on technology transfer achievements.
Furthermore, according to a previous announcement by Huiwen Biology, Liu Guiyun graduated from the First Medical College of Shanghai in 1982 with a postgraduate degree. From May 1956 to September 1979, she served as an assistant researcher at the Shanghai Institute of Plant Physiology of the Chinese Academy of Sciences, and later held positions such as researcher, senior engineer, and chief engineer at institutions such as the Shanghai Academy of Agricultural Sciences and the Shanghai Family Planning Research Institute.
It is worth mentioning that Liu Guiyun made significant contributions to Huiwen Biology’s star product, Tremella polysaccharide. Reportedly, Liu Guiyun, the founder of Huiwen Biology, collaborated with five scholars including Sun Ce, a pioneer in the polysaccharide field, Zhou Yunli, a renowned scientist in the field of medicinal chemistry at the Chinese Academy of Sciences, Yang Ruichang, an expert in plant extraction at the Shanghai Academy of Agricultural Sciences, and Wang Xiong, a specialist in cell physiology at the Institute of Botany of the Chinese Academy of Sciences, to initiate research on Tremella polysaccharides.
Currently, Huiwen Biology has grown into a well-known Chinese domestic cosmetic raw material company with multiple plant cultivation bases. Its products encompass cosmetic raw materials, food raw materials, and aim to utilize molecular biology drug research technologies to innovate the development of functional substances with independent intellectual property rights through various technical means (natural product extraction, fermentation, semi-synthesis, biosynthesis, organic synthesis) for application in various consumer sectors. This helps enhance the added value of their products for end-users and provide customer solutions, ultimately meeting the demand for market consumption upgrades.
In 2015, Huiwen Biology was officially listed on the New Third Board. According to the latest financial report up to the first half of 2024, Huiwen Biology’s revenue was 44.6602 million yuan, a decrease of 17.53% year-on-year, and the net profit was -991.75 million yuan, a decrease of 526.87% year-on-year. Regarding the decline in net profit, Huiwen Biology stated in the financial report that in the first half of the year, due to market reasons, the company’s sales revenue decreased year-on-year. Simultaneously, the company’s high investments in research and development as well as sales in the first half of the year led to a decrease in net profit.
According to Huiwen Biology’s financial report for the first half of 2024, the actual controllers of Huiwen Biology are Luo Feng, Luo Bin, and Liu Guiyun. Luo Feng and Luo Bin are brothers, and Liu Guiyun is the mother of Luo Feng and Luo Bin. The three collectively control 39.42% of the company’s shares through direct or indirect shareholdings. Additionally, Luo Feng serves as the Chairman and General Manager of the company, while Luo Bin serves as a Director and has a substantial impact on major operational decisions of the company.
Luo Feng, the Chairman and General Manager of Huiwen Biology, stated in an interview with CHAILEEDO, “Technology is a direction for the future development of the cosmetics market. We have always emphasized that sticking to the old ways is not enough to ensure the long-term competitiveness of Chinese companies; continuous innovation is necessary.”
Currently, domestically produced cosmetics with independently owned intellectual property, known as “Chinese components,” are becoming an important strategy for Chinese cosmetics to break through. Scientists of Liu Guiyun’s generation, actively engaging in material innovation, have driven the historical progress of the rise of Chinese cosmetics, leaving a significant mark on the history of the Chinese cosmetics industry.
